Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Activity and Tolerability of Maintenance Avelumab Immunotherapy After First Line Polychemotherapy Including Platinum in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma

Next Previous
Trial Profile

Activity and Tolerability of Maintenance Avelumab Immunotherapy After First Line Polychemotherapy Including Platinum in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary)
  • Indications Penile cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms PULSE

Most Recent Events

  • 18 Feb 2023 According Initial results presented at the 2023 Genitourinary Cancers Symposium, updated results with additional patients, longer follow-up and ancillary explorations with biomarkers analysis will be presented at the meeting.
  • 18 Feb 2023 Initial results (n=14) presented at the 2023 Genitourinary Cancers Symposium
  • 23 Feb 2022 Planned End Date changed from 1 Feb 2022 to 22 Sep 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top